XML 71 R42.htm IDEA: XBRL DOCUMENT
v3.23.4

Commitments and Contingencies - License Agreement (Details) - USD ($) |  |  |  |  |  |  | 1 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 28, 2022 | Jul. 29, 2022 | May 22, 2022 | Apr. 15, 2022 | Nov. 15, 2021 | Feb. 15, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | Nov. 30, 2020 | Oct. 31, 2020 | Nov. 30, 2018 | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time non-refundable fee of license agreement |  |  |  |  |  |  |  |  |  |  | $ 50,000 |  |  |
Reimbursement of Licensor's patent costs at execution of the License |  |  |  |  |  |  |  |  |  |  | 145,000 |  |  |
Minimum annual license fee |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  |  |
Period within each anniversary of the effective date of the License that minimum annual license fee must be paid |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |
Maximum total milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 1,550,000 | $ 1,550,000 |
Period within which the milestone payments should be paid upon achievement of the milestone |  |  |  |  |  |  |  |  |  |  |  | 60 days | 60 days |
Milestone payment due when enrollment of first patient in a phase II clinical trial of a therapeutic product or process |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 | $ 100,000 |
Milestone payment due when enrollment of first patient in a phase III clinical trial of a therapeutic product or process |  |  |  |  |  |  |  |  |  |  |  | 200,000 | 200,000 |
Milestone payment due when first commercial sale of a therapeutic product or process |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 1,000,000 |
Milestone payment due when filing of an application for regulatory approval of a clinical diagnostic product or process |  |  |  |  |  |  |  |  |  |  |  | 100,000 | 100,000 |
Milestone payment due when first regulatory approval of a clinical diagnostic product or process |  |  |  |  |  |  |  |  |  |  |  | $ 150,000 | $ 150,000 |
Royalties calculated as a percentage to on net sales of licensed products for therapeutic products or processes |  |  |  |  |  |  |  |  |  |  |  | 3.00% | 3.00% |
Royalties calculated as a percentage to on net sales of licensed products for clinical diagnostic products and processes |  |  |  |  |  |  |  |  |  |  |  | 6.00% | 6.00% |
Royalties calculated as a percentage of any and all sublicense income |  |  |  |  |  |  |  |  |  |  |  | 30.00% | 30.00% |
Notice period for terminating License |  |  |  |  |  |  |  |  |  |  |  | 90 days | 90 days |
Period after the first commercial sale that the License shall continue if not terminated by the company |  |  |  |  |  |  |  |  |  |  |  | 10 years | 10 years |
Royalty percentage beyond the term of the License |  |  |  |  |  |  |  |  |  |  |  | 1.50% | 1.50% |
Minimum annual license fee for Patent Family 1 |  |  |  |  |  |  |  |  | $ 30,000 | $ 25,000 |  |  |  |
Minimum annual license fee related to Patent Family 2 |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 | $ 10,000 |
Terms of option agreement with Licensor |  |  |  |  |  | 6 months |  |  |  |  |  |  |  |
Cost of option agreement |  |  |  | $ 7,500 |  | $ 5,000 |  |  |  |  |  |  |  |
Terms of extended option agreement with Licensor |  |  |  | 6 months |  | 6 months |  |  |  |  |  |  |  |
Cost of extended option agreement | $ 10,000 |  | $ 5,000 | $ 5,000 | $ 0 | $ 5,000 |  |  |  |  |  |  |  |
Computer-based phishing attack involving, amount |  |  |  |  |  |  |  | $ 526,435 |  |  |  |  |  |
Computer-based phishing attack involving recovery, amount |  |  |  |  |  |  | $ 45,682 |  |  |  |  |  |  |
Computer-based phishing attack involving recovery period |  |  |  |  |  |  | 5 days |  |  |  |  |  |  |
Computer based phishing attack, held by receiving bank pending resolution. |  |  |  |  |  |  | $ 480,753 |  |  |  |  |  |  |
Accrued license obligations |  |  |  |  |  |  |  |  |  |  |  | 61,322 | 57,820 | $ 20,487
University of Texas M. D. Anderson Cancer Center | collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Strategic Collaboration Agreement, Term |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |
Amount the company has committed to pay |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Amount the company has committed to pay in year one |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |
Subsequent payments made in first anniversary |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Subsequent payments made in second anniversary |  | 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Subsequent payments made in third anniversary |  | 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Subsequent payments made in fourth anniversary |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Total expenses incurred under the arrangement |  |  |  |  |  |  |  |  |  |  |  |  | 0 | $ 0
Maximum | Employee Severance |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate amount of severance |  |  |  |  |  |  |  |  |  |  |  | $ 2,483,700 | $ 2,483,700 |

X
- Definition It represents the amount of accrued license obligations. + References No definition available. + Details
Name: | rnaz_AccruedLicenseObligations
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The total expenses incurred under the collaborative arrangement. + References No definition available. + Details
Name: | rnaz_CollaborativeArrangementExpensesIncurred
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of computer based phishing attack, held by receiving bank pending resolution. + References No definition available. + Details
Name: | rnaz_ComputerBasedPhishingAttackHeldByReceivingBankPendingResolution
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of computer based phishing attack involving. + References No definition available. + Details
Name: | rnaz_ComputerBasedPhishingAttackInvolving
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of computer based phishing attack involving recovery. + References No definition available. + Details
Name: | rnaz_ComputerBasedPhishingAttackInvolvingRecovery
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Computer based phishing attack involving recovery period. + References No definition available. + Details
Name: | rnaz_ComputerBasedPhishingAttackInvolvingRecoveryPeriod
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation Committed to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | rnaz_ContractualObligationAmountCommittedToBePaidInYearOne
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the cost of extended option agreement. + References No definition available. + Details
Name: | rnaz_CostOfExtendedOptionAgreement
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cost of option agreement. + References No definition available. + Details
Name: | rnaz_CostOfOptionAgreement
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It represents the maximum total milestone payments. + References No definition available. + Details
Name: | rnaz_MaximumTotalMilestonePayments
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the milestone payment due when enrollment of first patient in a phase II clinical trial of a therapeutic product or process. + References No definition available. + Details
Name: | rnaz_MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiClinicalTrialOfTherapeuticProductOrProcess
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the milestone payment due when enrollment of first patient in a phase III clinical trial of a therapeutic product or process. + References No definition available. + Details
Name: | rnaz_MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiiClinicalTrialOfTherapeuticProductOrProcess
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the milestone payment due when filing of an application for regulatory approval of a clinical diagnostic product or process. + References No definition available. + Details
Name: | rnaz_MilestonePaymentDueWhenFilingOfApplicationForRegulatoryApprovalOfClinicalDiagnosticProductOrProcess
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the milestone payment due when first commercial sale of a therapeutic product or process. + References No definition available. + Details
Name: | rnaz_MilestonePaymentDueWhenFirstCommercialSaleOfTherapeuticProductOrProcess
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the milestone payment due when first regulatory approval of a clinical diagnostic product or process. + References No definition available. + Details
Name: | rnaz_MilestonePaymentDueWhenFirstRegulatoryApprovalOfClinicalDiagnosticProductOrProcess
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition It represents the minimum annual license fee. + References No definition available. + Details
Name: | rnaz_MinimumAnnualLicenseFee
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual license fee for Patent Family 1. + References No definition available. + Details
Name: | rnaz_MinimumAnnualLicenseFeeForPatentFamily1
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual license fee related to Patent Family 2. + References No definition available. + Details
Name: | rnaz_MinimumAnnualLicenseFeeRelatedToPatentFamily2
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It represents the notice period for terminating License. + References No definition available. + Details
Name: | rnaz_NoticePeriodForTerminatingLicense
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the one-time non-refundable fee for license of license agreement. + References No definition available. + Details
Name: | rnaz_OneTimeNonRefundableFeeOfLicenseAgreement
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It represents the period after the first commercial sale that the License shall continue if not terminated by the company. + References No definition available. + Details
Name: | rnaz_PeriodAfterFirstCommercialSaleThatLicenseShallContinueIfNotTerminatedByCompany
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the Period within each anniversary of the effective date of the License that minimum annual license fee must be paid. + References No definition available. + Details
Name: | rnaz_PeriodWithinEachAnniversaryOfEffectiveDateOfLicenseThatMinimumAnnualLicenseFeeMustBePaid
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the period within which the milestone payments should be paid upon achievement of the milestone. + References No definition available. + Details
Name: | rnaz_PeriodWithinWhichMilestonePaymentsShouldBePaidUponAchievementOfMilestone
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the reimbursement of Licensor's patent costs at execution of the License. + References No definition available. + Details
Name: | rnaz_ReimbursementOfLicensorsPatentCostsAtExecutionOfLicense
Namespace Prefix: | rnaz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties calculated as a percentage of any and all sublicense income. + References No definition available. + Details
Name: | rnaz_RoyaltiesCalculatedAsPercentageOfAnyAndAllSublicenseIncome
Namespace Prefix: | rnaz_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the royalties calculated as a percentage to on net sales of licensed products for clinical diagnostic products and processes. + References No definition available. + Details
Name: | rnaz_RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForClinicalDiagnosticProductsAndProcesses
Namespace Prefix: | rnaz_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the royalties calculated as a percentage to on net sales of licensed products for therapeutic products or processes. + References No definition available. + Details
Name: | rnaz_RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForTherapeuticProductsOrProcesses
Namespace Prefix: | rnaz_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty percentage beyond the term of the License. + References No definition available. + Details
Name: | rnaz_RoyaltyPercentageBeyondTermOfLicense
Namespace Prefix: | rnaz_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of strategic collaboration agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rnaz_StrategicCollaborationAgreementTerm
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the terms of extended option agreement with Licensor. + References No definition available. + Details
Name: | rnaz_TermsOfExtendedOptionAgreementWithLicensor
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Terms of option agreement with Licensor. + References No definition available. + Details
Name: | rnaz_TermsOfOptionAgreementWithLicensor
Namespace Prefix: | rnaz_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInFourthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInNextTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInSecondYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInThirdYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_SeveranceCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rnaz_UniversityOfTexasM.D.AndersonCancerCenterMdAndersonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |